Skip to main content
Clinical Trials/EUCTR2007-002080-27-GB
EUCTR2007-002080-27-GB
Active, not recruiting
Not Applicable

A randomised, double-blind controlled trial of ketamine versus placebo in conjunction with best pain management in neuropathic pain in cancer patients - KPS

Greater Glasgow Health Board/University of Glasgow0 sites214 target enrollmentJune 27, 2008

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Greater Glasgow Health Board/University of Glasgow
Enrollment
214
Status
Active, not recruiting
Last Updated
10 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 27, 2008
End Date
TBD
Last Updated
10 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Greater Glasgow Health Board/University of Glasgow

Eligibility Criteria

Inclusion Criteria

  • \> 18 years of age
  • Patient has a histological proven cancer diagnosis
  • Written informed consent (to be obtained within 28 days prior to entry into the study)
  • Index neuropathic pain (as defined by LANSS) that is related to underlying malignancy or resulting from treatment received for this
  • Index neuropathic pain \>\= 4 on 0\-10 (VAS)
  • McGill Sensory Scale Score \> 5
  • Patient has had a trial of at least one adjuvant analgesic (gabapentin, pregabalin, amitriptyline) or has been offered these and declined
  • Patient is able to comply with study procedures
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:

Exclusion Criteria

  • Patients who have received chemotherapy or radiotherapy in the preceding six weeks that is likely to affect neuropathic pain
  • Patients who may have a change in tumoricidal treatment during the period of the study that is likely to alter pain during the course of the study
  • Diastolic blood pressure \> 100mmHg at screening
  • History of seizures in last 2 years
  • Patient is currently taking class I anti\-arrhythmic drugs
  • Life expectancy less than two months
  • Patients who are actively hallucinating
  • Women of childbearing potential who are not using adequate contraception
  • Patients with cerebrovascular disease (strokes)
  • Patients with psychotic disorders or cognitive impairment

Outcomes

Primary Outcomes

Not specified

Similar Trials